# An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

> **NCT03533283** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 211 (actual)

## Conditions studied

- Non-Hodgkins Lymphoma

## Interventions

- **DRUG:** Glofitamab
- **DRUG:** Atezolizumab
- **DRUG:** Obinutuzumab
- **DRUG:** Tocilizumab
- **DRUG:** Polatuzumab Vedotin
- **DRUG:** 89Zr-Df-IAB22M2C

## Key facts

- **NCT ID:** NCT03533283
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-05-08
- **Primary completion:** 2026-10-16
- **Final completion:** 2026-10-16
- **Target enrollment:** 211 (ACTUAL)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03533283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03533283, "An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT03533283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*